(See the editorial commentary by Schlievert, on pages 676-8.)
. Panton-Valentine leukocidin (PVL) toxin lyses human but not murine polymorphonuclear cells (PMNs) in a time-and concentrationdependent fashion. The recombinant LukS-PV and LukF-PV proteins, mixed at equimolar concentrations, were incubated at room temperature with either human PMNs/mL (A and B) or murine PMNs 6 6 2.0 ϫ 10 1.0 ϫ 10 or peritoneal exudate cells (PECs)/mL (B) in a total of 340 mL reaction mixture. The time course of the cell lysis was monitored after 15, 30, 60, 90, and 120 min incubation (A) and after 60 min (B). After washing twice with phosphate-buffered saline (PBS Ϫ ), each sample was subjected to measurement of pore formation by flow cytometry.
CA-MRSA strains [28] . In addition, Voyich et al. reported that PVL is not a major virulence determinant in diseases due to CA-MRSA [29] . Using the isogenic PVL-negative derivative strains, the authors obtained the data indicating that PVL did not contribute to virulence in mouse sepsis or abscess models. Moreover, the ability to lyse human neutrophils was similar for both PVL-positive and PVL-negative isogenic strains.
To objectively reevaluate the role of PVL in the greater virulence of certain CA-MRSA strains, we obtained recombinant PVL proteins by use of the glutathione-S-transferase (GST) fusion system and raised PVL-specific monoclonal antibodies. Using these materials, we established an assay of PVL-mediated human PMN lysis. We report here that PVL does contribute to the cytolysis of human PMNs, and PSMs have a role in augmenting the PVL-mediated lysis of human PMNs.
MATERIALS AND METHODS
Bacterial culture. The S. aureus strains used in this study were USA400 MW2 [30] , USA400 AIS2002056 [30] , USA300 (FPR3757) [31] , C1999000193 (JCSC2152) [23] , A80 3355 [32, 33] , V8 (ATCC49775) [6] , 81/108 [26] , USA500 AIS2002057, USA1000 AIS2002061, USA1100 AIS2002062 [34, 35] , and N315 [36] .
Each S. aureus strain was precultured in 4.0 mL of brainheart infusion broth (BD Difco) at 37ЊC overnight, then adjusted with fresh brain-heart infusion to an optical density of 0.3 read at 575 nm. Each strain was then further diluted 1000-fold by use of casein hydrolysate and yeast-extract containing modified medium [6, 37] and cultivated at 37ЊC with 5% CO 2 for 18 h. The culture supernatants were then isolated for use in the subsequent experiments.
Production and purification of recombinant PVL proteins. Production of recombinant proteins of PVL was carried out using the GST fusion system [38, 39] . In brief, we used the specific primers to amplify lukS-PV and lukF-PV genes as reported elsewhere [40] . Primers contained BamHI or SalI restriction sites; the purified polymerase chain reaction products were treated with restriction enzymes and then cloned into the corresponding sites of plasmid pGEX-4T3 (GE Healthcare BioSciences), allowing in-frame fusion with GST. After introduction of the plasmids into Escherichia coli JM109, the GST-LukS-PV or GST-LukF-PV fusion proteins were overexpressed by adding isopropyl-b-thiogalactopyranoside up to a concentration of 2 mmol/L to the E. coli cultivated in Luria-Bertani broth containing 100 mg/mL of ampicillin (Wako Pure Chemical Industries).
Recombinant proteins were purified in accordance with the manufacturer's instructions (GE Healthcare Bio-Sciences). In brief, the GST fusion proteins (GST-LukS-PV and GST-LukF-PV) were purified from lysates of transfected E. coli cells by use of affinity chromatography and a Glutathione Sepharose 4B column (GE Healthcare Bio-Sciences); target fusion proteins were eluted with 10 mmol/L reduced glutathione (pH 8.1; Sigma). The fusion proteins were cleaved by ∼200 units of thrombin protease treatment (GE Healthcare Bio-Sciences) at room temperature and further concentrated. The protein concentration was determined by use of the Bradford method (Bio-Rad Laboratories) [41] . The purity of the fusion proteins 1.0 ϫ 10 2.0 ϫ 10 mL of human PMNs or murine peritoneal exudate cells (PECs) for 60 min at room temperature. The PSMa3 peptide at concentrations of 0.6-31.3 mg/mL was incubated with human PMNs for 3, 5, 10, 15, 30, 60, 90, and 120 min at room temperature. After washing twice with phosphatebuffered saline, each sample was subjected to the measurement of the pore formation by flow cytometry. was verified by use of 12% SDS-PAGE followed by Coomassie brilliant blue staining (32 kDa for LukS-PV and 34 kDa for LukF-PV).
Synthesis of PSM peptides. PSMa3 with the amino acid sequence NH 2 -MEFVAKLFKFFKDLLGKFLGNN-COOH [28, 30] were synthesized by Operon Biotechnologies (Tokyo, Japan) and purified to 190% by use of high-performance liquid chromatography.
Preparation of human PMNs. PMNs were isolated from heparinized venous blood obtained from healthy adult volunteers. First, whole blood samples were layered onto a density gradient medium (Polymorphprep; Axis-Shield), as described elsewhere [42] . The tube was then subjected to centrifugation at 500 g for 45 min at room temperature. The PMN-containing fraction was harvested and washed with 0.05% EDTA-2Na-Dulbecco's phosphate-buffered saline (Nissui Pharmaceutical) to remove platelet fragments, followed by centrifugation at 300 g for 10 min. The cells were suspended in 10 mL of 0.2% sodium chloride and incubated for 120 s to lyse erythrocytes by osmotic shock, followed by the addition of 10 mL of 1.6% sodium chloride for 120 s to normalize the osmolality. Purified PMNs were washed twice with phosphate-buffered saline (PBS Ϫ ) and enumerated by using a hemacytometer (BurkerTurk line, ERMA). The purity and cell viability of the PMN preparation were assessed by use of microscopic inspection with the 0.5% Trypan blue dye exclusion method and flow cytometric profiles of cell distributions. More than 95% of viable cells were obtained. The final PMN count was adjusted to to cells/mL with RPMI 1640 (Sigma) con- 6 6 1.0 ϫ 10 2.0 ϫ 10 taining 1.0% wt/vol bovine serum albumin (BSA) (Chon Fraction V powder; Iwai Chemicals).
Casein-induced peritonitis. Mouse PMNs were separated as described elsewhere [43] . First, 2.0 mL of 2.0% casein sodium (Wako Pure Chemical Industries) dissolved in cold PBS Ϫ was injected into the peritoneal cavity of 6 to 7-week-old BALB/c female mice (Japan SLC). Four to five hours after the injection, the mice were anesthetized by use of ether inhalation and euthanized, followed by 2 intraperitoneal injections of 3.0 mL of sterilized cold PBS Ϫ . Peritoneal lavage was used to harvest peritoneal exudate cells (PECs) into a polyethylene tube containing RPMI 1640 medium and 1.0% wt/vol BSA. Subsequent procedures were the same as those described for preparation of human PMNs. Approximately to PMNs/mL 6 6 2.0 ϫ 10 5.0 ϫ 10 were harvested per mouse, and the final PMN count was adjusted to to cells/mL with RPMI 1640 6 6 1.0 ϫ 10 2.0 ϫ 10 (Sigma) containing 10% wt/vol BSA. In addition to this, heparinized whole blood samples were also collected from the aortas of BALB/c female mice, and PMNs were separated by use of the same method as described for preparation of human PMNs.
All experimental protocols using animals were reviewed by The concentrations of PVL in the culture supernatants were calculated on the basis of the sensitivity of the latex agglutination assay [40] .
the Institutional Animal Care and Use Committee of the Juntendo University School of Medicine, in compliance with applicable national laws and regulations and the institutional guidelines on animal experimentation. Flow cytometric analysis. PVL-mediated or/and PSMa peptide-mediated membrane pore formation and cell lysis both in human and mouse PMNs were evaluated by recording cellular propium iodide (Sigma-Aldrich Japan) incorporation in the flow cytometric assay, as described elsewhere [44, 45] . The following 3 PVL solutions were prepared: (1) equimolar solutions of both LukS-PV and LukF-PV recombinants, (2) LukS-PV protein only, and (3) LukF-PV protein only. The solutions were preincubated for 30 min at 4ЊC in the presence or absence of anti-PVL mouse monoclonal antibodies (anti-LukS-PV mAb and anti-LukF-PV mAb). In some experiments, PVL-mediated cell lysis was investigated in the presence or absence of PSMa3. Then, 300 mL of PMN suspension ( to cells/ 6 6 1.0 ϫ 10 2.0 ϫ 10 mL) was mixed with the PVL solutions for 15-120 min of reaction time, followed by washing twice with PBS Ϫ . Finally, the cells were resuspended in PBS Ϫ and stained with 4.49 mmol/ L of propium iodide for 15 min at 37ЊC. Flow cytometric evaluation was carried out by using a FACScan flow cytometer (Becton Dickinson) equipped with a 15-mW argon laser, the wavelength of which was adjusted to 488 nm. Cell lysis was determined by recording fluorescence change due to propium iodide uptake. Data were analyzed with Cell Quest software (Becton Dickinson), and results were expressed as the percentage of propium iodide-positive cells. Quantification of PVL and PSMa production in S. aureus clinical strains. Each bacterial supernatant was subjected to quantitative determination of PVL and PSMa3 peptides. To determine the quantity of PVL, we used the latex agglutination assay [40] . Twenty-five microliters of each supernatant harvested from cultured S. aureus was serially diluted with the reaction buffer from 1:2 to 1:10,000 in a 96-well microtiter plate. Subsequent procedures were the same as those described elsewhere [40] . The end point of agglutination was judged visually, and the PVL concentration was calculated by multiplying the detection limit concentration (1 ng/mL) by the dilution value for the greatest dilution that had a positive agglutination result.
To quantify the PSM peptides, each supernatant was subjected to centrifugation at 21,000 g for 15 min at 4ЊC. Supernatants were then subjected to reversed-phase high-performance liquid chromatography-electrospray mass spectrometry in which the N-terminal formylated and deformylated synthesized peptides were used as standards.
RESULTS
Lysis of human and murine PMNs by recombinant PVL, relative to both concentration and time. PVL-mediated lysis of PMNs was evaluated by use of flow cytometry. Neither of the recombinant proteins-LukS-PV or LukF-PV-could cause lysis of human PMNs when tested individually (data not shown). In contrast, when an approximately equimolar mixture of the 2 components was used, it evoked cell lysis in a concentrationand time-dependent manner (figure 1). The percentage of lysed PMNs increased up to 120 min in an almost linear fashion, and 190% of PMNs were lysed when a 130 nmol/L (0.99 mg/ mL) concentration of LukS-PV and LukF-PV recombinant proteins was used. On the other hand, no activity of the recombinant PVL proteins was observed against either casein-induced PECs or the PMNs separated from the whole blood of BALB/c female mice ( figure 1B) .
Lysis of both human and murine PMNs by PSMa. The 1.0 ϫ 10 2.0 ϫ 10 60 min. After washing twice with phosphate-buffered saline, each sample was subjected to measurement of pore formation by flow cytometry.
a-type PSM peptides are reported to have greater proinflammatory and PMN-lytic activity than b-type PSMs [28, [46] [47] . Because PSMa3 is reported to be the major and most potent component of the a-type PSMs, we evaluated PSMa3-mediated cell lysis for human and murine PMNs by using a synthesized PSMa3 peptide. Unlike PVL toxin, PSMa3 caused cell lysis of both human and murine PMNs. However, a concentration of PSMa3 13.0 mg/mL was required to produce appreciable lysis of the PMNs ( figure 2A ). This concentration is comparable to that in the undiluted culture supernatants of the highly PSMproducing strains, such as the USA300 FPR3757 or USA400 MW2 strain (see below). It was also notable that the lysis mediated by PSMa3 was considerably more rapid than that induced by PVL and was rather concentration dependent ( figure  2B ). This indicates that PSMa3 has a different mode of action against human PMNs than does PVL.
Quantitation of PVL produced by S. aureus strains with different backgrounds. PVL genes are carried by S. aureus clinical strains with diverse genetic backgrounds [33, 40] . Latex beads conjugated with anti-PVL antibodies [40] revealed great variation in the amount of PVL produced by pvl gene-positive strains with various genetic backgrounds. Table 1 shows the concentration of PVL in the supernatants of the strains used in this study. The USA300 pulsotype FPR3757 strain produced the greatest amount of PVL (у12.5 mg/mL of LukS-PV and 25.0 mg/mL of LukF-PV). The amount of PSMa3 produced by the strain was 2.47 mg/mL.
Synergy between PVL and PSMa3 in lysing human PMNs. Figure 3A shows the results of lysis of human PMNs caused by PVL in the presence of PSMa3. The lysis was significantly augmented in the presence of various concentrations of PSMa3 peptides. It was noted that PSMa3 peptides did not enhance the lysis of PMNs in the presence of either LukS-PV or LukF-PV alone ( figure 3B ). On the basis of this result, we concluded that the major component responsible for lysis was PVL. In contrast, no synergistic lysis of murine PMNs was observed in the presence of the 2 PVL components (in concentrations from 0.03-0.13 mg/mL) and up to 2.8 mg/mL of PSMa3 (data not shown). We concluded that the absence of enhanced lysis of murine PMNs occurred because murine PMNs were not sensitive to PVL. Figure 4A shows the results of the neutralization activity of anti-PVL monoclonal antibodies. The lytic action of PVL toxin was completely neutralized when it was preincubated with concentrations of anti-LukS-PV and anti-LukF-PV monoclonal antibodies у1.1 mg/mL. Molar ratios of anti-PVL monoclonal antibodies to PVL toxins greater than ∼1.0 were required to neutralize the PVL-mediated PMN lysis. There was no statistically significant difference in the neutralizing effect for preincubation times from 30 to 60 min and temperatures between 4ЊC and 37ЊC (data not shown). Moreover, the neutralization activity of the anti-PVL monoclonal antibodies was unchanged, even in the presence of PSMa3 ( figure 4B ). Use of a single monoclonal antibody (ie, either one of the anti-LukS-PV or anti-LukF-PV monoclonal antibodies) did inhibit PMN lysis, but this effect was less potent than that of the 2 antibodies combined (data not shown). On the other hand, isotype-specific purified murine antibody, IgG 1 k (anti-TNP; BD PharMingen) with an irrelevant binding specificity had no inhibitory effect on PVL-mediated PMN lysis ( figure 4A ).
Anti-PVL monoclonal antibodies and inhibition of lysis of human PMNs by PVL toxin.
PMN-lytic activity of USA400 MW2 and USA300 FPR3757 supernatants and its inhibition by anti-PVL monoclonal antibodies. In a recent study, Voyich et al claimed that there was no PVL-mediated lysis observed to result from adding the culture supernatant of USA 400 MW2 or USA300 strain LAC to cultured cell [29] . Using our PMN-lytic assay system, we tested whether their observation was reproducible. Appropriately diluted culture supernatants from USA400 MW2 and USA300 FPR3757, either with or without preincubation with anti-PVL monoclonal antibodies for 30 min at 4ЊC, were added to cultures of human PMNs. Figure 5 shows the time course of PMN lysis for each supernatant from the USA400 MW2 and USA300 FPR3757 strains. Initially, we noticed that unlike the lytic pattern of PSMa3, this lysis process increased in intensity over time. Both supernatants lysed human PMNs in a concentration-dependent manner. When the culture supernatants of USA400 MW2 or USA300 FPR3757 were preincubated with anti-PVL monoclonal antibodies, the PMN-lytic activities for 2-hour reactions were significantly inhibited in the presence of anti-PVL monoclonal antibodies (figure 6).
DISCUSSION
The flow cytometric assay system used in this study could sensitively detect the toxin-mediated elevation of membrane leakage by monitoring the change in fluorescence over time. Recombinant PVL proteins formed pores in human PMNs in a concentration-and time-dependent manner (figure 1). On the other hand, the PMNs taken from BALB/c female mice were not sensitive to PVL. Therefore, unlike the previously described bicomponent synegohymenotropic toxins such as Hla, Hlg, Hld, and LukED, PVL seems to act specifically on human but not murine PMNs. This may explain why researchers who used mouse experimental models reached different conclusions about the role of PVL in the virulence of CA-MRSA [19, 29] . We need to seek a better animal model for precise evaluation of the role of PVL, because mouse PMNs are resistant to PVL action. Diep et al reported a definite role for PVL in the acute phase of bacteremia in a rabbit infection model, indicating that rabbit PMNs are more sensitive to PVL than murine PMNs [48] .
Labandeira-Rey M et al directly evaluated PVL-mediated lung pathogenicity using a lung infection model in BALB/c mice [19] . They concluded that the pulmonary histopathological diseases were definitively caused by PVL. On the other hand, Bubeck Wardenburg et al showed that a-toxin-but not PVLplays an important role in inducing pneumonia in mice infected with a clinically relevant CA-MRSA strain [49] . It should be noted that our study is confined to the activity of PVL in 1.0 ϫ 10 2.0 ϫ 10 temperature. After washing twice with phosphate-buffered saline, each sample was subjected to measurement of pore formation by flow cytometry. CCY, casein hydrolysate and yeast-extract containing modified medium.
the lysis of PMNs. Therefore, our experiments do not disprove or prove the results of the studies mentioned above, which are targeted at the role of PVL in lung tissue pathogenesis. At present, we have neither information nor data regarding the contribution of other virulence factors such as a-and g-toxin to necrotizing pneumonitis.
Although some CA-MRSA strains produce increased amounts of PSMs in comparison with other groups of MRSA, such as healthcare-associated MRSA strains, their concentrations in the undiluted culture supernatants do not reach 10 mg/mL [28] . The supernatants of the 2 CA-MRSA strains tested in the present study contained ∼1.0-3.0 mg/mL of PSMa3 and 3.0-25.0 mg/mL of PVL. At this concentration synergy is expected to occur, although PSMa3 alone would not cause appreciable amounts of PMN lysis ( figure 2A) . Therefore, we consider that the major role of the PSM peptides produced in large amounts by some CA-MRSA strains is the enhancement of the PVL-mediated PMN lysis rather than the lysis of PMNs as a single lytic agent.
The mechanism of the synergy between PSM and PVL remains to be clarified. Since the lysis-enhancing effect of PSMa3 was observed only when the 2 components of PVL toxinLukS-PV and LukF-PV-were present, it is evident that the synergistic action of PSMa3 was not the result of the physical association of PSMa3 with either of the PVL component proteins. Moreover, the lysis was completely inhibited by monoclonal antibodies specific to PVL toxins. We consider that PSMs, with their amphipathic a-helical structures, may serve as detergents to disintegrate cell membranes that have already been damaged by PVL-mediated pore-formation.
Other PSM peptides with less activity than PSMa3 were not measured in our study. Therefore, additional effects from the other PSMs may result in a several-fold increase in the lytic activity of the supernatants. However, PSMa3 is considered to be the most potent member of the PSMs, and the total amounts of PSMs produced by each bacterial strain are only several-fold greater than the amount of PSMa3 [28] . Therefore, in the 1: 50 and 1:100 dilutions of the supernatants used in our study, the total concentration of PSMs should be much lower than the smallest concentration of PSMa3 tested in this study (0.3 mg/mL; see figure 3A ). At these concentrations, the PMN-lytic activity of the supernatants was significantly inhibited by anti-PVL monoclonal antibodies (figure 6). Therefore, it is unlikely that the simultaneous presence of all the members of the PSM peptide group would be more cytolytic to human PMNs in the absence of PVL toxins.
Voyich et al reported that the PMN-lytic activity of culture supernatants of CA-MRSA strains USA400 MW2 and USA300 LAC were not affected by the deletion of pvl genes and concluded that the lytic activity was not the result of PVL activity [29] . In their study, the supernatants were diluted more than 250 times. However, because of the dilution, the PVL concentration in the culture supernatant should have become too low to manifest lytic activity. In addition, the reaction time used in their study (30 min) was much shorter than ours (our reaction time was up to 120 min). Although their data and ours appear discrepant, they might have detected the PVL-mediated activity if they had tested less diluted supernatants and used a longer reaction time. 1.0 ϫ 10 2.0 ϫ 10 temperature. The final dilution of each supernatant in the reaction mixture is given in the figures. After washing twice with phosphate-buffered saline, each sample was subjected to measurement of pore formation by flow cytometry.
In this study, we used the latex bead agglutination test we developed for the quantitation of PVL toxins produced by S. aureus clinical strains [40] . We found that not all pvl-carrying S. aureus strains are potent producers of PVL. Moreover, there are 11000-fold differences in the amount of PVL in the culture supernatants of pvl-carrying S. aureus strains (as described elsewhere [40] and in Y.M., unpublished observations). The concentration of PVL in the culture supernatant of USA300 FPR3757 was extremely high and was ∼10-21 times higher than the concentration of PVL required for the lysis of 95% human PMNs in our assay system (figure 1A). In contrast, another PVL-producing, strain MR81/108, produced only a marginal amount of PVL, and the production level did not increase at all despite using several different culture media (data not shown). Therefore, we consider the ability to produce a large amount of PVL toxin may be an important feature of highly virulent CA-MRSA strains, rather than mere possession of the pvl gene. Although we make no reference to the role of PVL in determining the severity of disease, we have shown its definite role in the lysis of human PMNs. We believe that this lysis is important in S. aureus colonization and in the further development of infection via the disruption of the innate immune system in humans. A more extensive survey of clinical strains from this viewpoint would be warranted, with the goal of better understanding of the high virulence levels of certain CA-MRSA strains. In this regard, the anti-PVL monoclonal antibodies would serve not only as a useful tool for detection of the PVLproducing S. aureus strains but also as a supplemental therapeutic option for treatment of CA-MRSA infections due to PVL-positive strains.
